护骨素基因多态性与阿仑膦酸钠治疗绝经后骨质疏松骨密
度变化的关系
汪纯;何进卫;秦跃娟;张浩;胡伟伟;刘玉娟;章振林
【期刊名称】《中华医学杂志》 【年(卷),期】2009(089)042
【摘要】Objective To investigate whether the polymorphism of osteoprotegerin(OPG)gene is associated with the change of BMD(bone mineral density)after alendronate therapy in postmenopausal women with osteoporosis and determine the correlation between genotypes and therapeutic effect.Methods Eighty postmenopausal osteoporotic patients were recruited with an average age of(64.2±7.7)years old. Every patient took oral alendronate(Fosamax)70 mg weekly and Caltrate 600 mg daily for 12 months.At pre-and post-treatment.BMD was measured at lumbar spine 2-4 and hip sites.PCR-RFLP was performed for three polymorphisms at the promoter site of OPG gene(A163G,T245G and T950C).Results
One-year
therapy
was
accomplished
in
67
patients.Patients with G allele(genotype AG and GG)of site A163G,the baseline BMD of vertebral L2-4,inter-troche and total hip were lower than
genotype
AA[(0.732±0.113)g/cm~2
vs(0.819±0.157)g/cm~2,(0.775±0.101)g/cm~2 vs(0.843±0.124)g/cm~2 and(0.667±0.105)g/cm~2 vs(0.725±0.091)g/cm~2].Patients with G allele(genotype TG and GG)of site T245G,baseline BMD of vertebral L2-4,
护骨素基因多态性与阿仑膦酸钠治疗绝经后骨质疏松骨密度变化的关系
